Aims and Scope

ReviewerCreditsCurrent Cancer Reports (CCR) (eISSN: 2661-3166) is an open access, continuously published, international, refereed journal dedicated to publish articles covering all areas of carcinogenesis, prevention, diagnosis, treatment, drug development and related policy.

The journal aims at promoting research communications, and providing a platform for doctors, researchers, physicians, pharmacists and healthcare professionals to find the most recent advances in all areas of cancer-related fields. Current Cancer Reports accepts original research articles, reviews, minireviews, case reports, image data, novel hypothesis and rapid communication covering all respects of carcinogenesis and cancer therapy.

The columns of the journal include, but not limited to:
• Original articles and new techniques in cancer research and therapy
• Quick reports
• Case reports
• Clinicopathologic discussion
• Discussion of clinical case
• Expert views
• Exchange of experience
• Novel hypothesis
• Correspondence
• Publish the original incoming letter
• Academic contending/Debate
• etc.

Vol 6 No 1 (2024)

Published: 2024-07-02

Abstract views: 178   PDF downloads: 41  

Page 193-204

Nanotherapeutics to cure inflammation-induced cancer

blankpage Rajiv Kumar

Aims: Nanotherapeutics are being explored as a potential solution to treat inflammation-induced cancer. Nanotherapeutics enhance innate immune cells' immunity, enabling them to fight tumors effectively. These cells secrete specific chemicals like cytokines, allowing them to replicate quickly and respond to future threats, making them suitable for immunotherapy.
Methods: Nanotechnology can significantly improve human health by enhancing infection detection, prevention, and treatment. Nanomedicines, composed of restorative and imaging compounds in submicrometer-sized materials, aim to deliver effective treatments and limit inflammation in healthy body areas. Combining nanotechnology and clinical sciences, nanoparticles are suitable for gene therapy and have been developed for treating various diseases, including cancer, cardiovascular, diabetes, pulmonary, and inflammatory diseases.
Results: Neutrophils and their offspring, including films and extracellular vehicles, are crucial drug transporters for enhanced growth therapy. Tumor microenvironment inputs can modify tumor-associated neutrophils (TANs), which are essential for tumor growth and healing. Human tumor intratumor heterogeneity is crucial for tumor growth and healing. Nanomedicines have shown potential in targeted delivery, toxicity reduction, and therapeutic effectiveness enhancement. However, clinical relevance and efficacy remain inadequate due to a lack of understanding of the interaction between nanomaterials, nanomedicine, and biology. The diverse biological milieu impacts the dynamic bioidentity of nanoformulations, and their interactions can modify therapeutic function or cellular absorption.
Conclusion: Nanotechnology holds great promise for improving human health by detecting, preventing, and treating infections. Nanomedicines, a fusion of clinical sciences and nanotechnology, use submicrometer-sized transporter materials for therapy delivery and reducing contamination. Nanoparticles' small size and high surface-to-volume ratio can benefit gene therapy. Research has led to a wide range of nanomedicine products globally.

View All Issues
Yuesuo Yang-photo  eISSN: 2661-3166
 Abbreviation: Curr Cancer Rep
 Editor-in-Chief: Prof. Yingyu Cui
 Publishing Frequency: Continuous publication
 Article Processing Charges (APC):
Click  here  for more details
 Publishing Model:
Open Access